Last reviewed · How we verify
GSK2248761 reference formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK2248761 reference formulation (GSK2248761 reference formulation) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK2248761 reference formulation TARGET | GSK2248761 reference formulation | ViiV Healthcare | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK2248761 reference formulation CI watch — RSS
- GSK2248761 reference formulation CI watch — Atom
- GSK2248761 reference formulation CI watch — JSON
- GSK2248761 reference formulation alone — RSS
Cite this brief
Drug Landscape (2026). GSK2248761 reference formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2248761-reference-formulation. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab